FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $216,208 | -88.3% | 101,985 | -73.8% | 0.00% | -85.7% |
| Q2 2023 | $1,849,508 | -0.0% | 388,552 | +19.7% | 0.01% | -74.1% |
| Q1 2023 | $1,849,690 | +292.5% | 324,507 | +594.8% | 0.03% | +200.0% |
| Q4 2022 | $471,253 | +12.5% | 46,705 | +149.8% | 0.01% | +12.5% |
| Q3 2022 | $419,000 | -60.2% | 18,700 | -31.2% | 0.01% | -71.4% |
| Q1 2022 | $1,054,000 | +294.8% | 27,175 | +503.2% | 0.03% | +250.0% |
| Q3 2021 | $267,000 | -65.1% | 4,505 | -46.4% | 0.01% | -84.3% |
| Q4 2020 | $765,000 | – | 8,410 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |